Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INAVAC Heterologous Booster in Adolescents
NCT06272253Phase 1Active, not recruiting
- Sponsor
- Dr. Soetomo General Hospital
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of salmonella typhi capsular polysaccharide vaccine in coronavirus disease 2019 (COVID-19), sponsored by Dr. Soetomo General Hospital. Primary endpoint: Humoral Immune Response (Neutralizing antibody) at 28 days. Started Sep 2023; status: active, not recruiting.
02
Drugs
salmonella typhi capsular polysaccharide vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06272253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06272253.